According to a new research report “Global Bromodomain and Extra-Terminal (BET) Inhibitors Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments”, published by P&S Intelligence, BET inhibitors currently exhibit a strong pipeline with estimated 38 drug candidates.
Browse the Report Summary at: https://www.psmarketresearch.com/market-analysis/bet-inhibitors-pipeline-analysis
BET inhibitors offer novel therapeutic approach for cancer
The study analyzed that the BET inhibitors pipeline comprised 38 drug candidates in different stages of development.
Insights on pipeline segments
As per the findings of the research, most of the BET inhibitor pipeline drug candidates are being developed to be administered by oral route.
IC50 value and Kd of different types of BET inhibitors
In BET inhibitors, IC50 value is measured as the concentration of drug at which 50% of the target is inhibited. IC50 is a pharmacokinetic measure; the lower the IC50 of drug candidate, the lesser the desired effect, and the less likelihood of the drug to have some off-target effect. Kd is known as dissociation constant of drug. It measures the rate of dissociation of the drug and its binding affinity. Birabresib (MK8628), a BET inhibitor by Merck & Co., has IC50 value of 100nM.
Strategic collaborations for the development of BET inhibitors
The research finds that different companies are collaborating for the development of BET inhibitors. In January 2017, ConverGene had entered into a sponsored research agreement with the University of Maryland, Baltimore to investigate the in vivo anti-leukemic effects of ConverGene’s lead BET inhibitor drug candidates, CG223 and CG250.
Some of the key players developing BET inhibitors are Resverlogix Corp., GlaxoSmithKline plc, Bristol-Myers Squibb Company, and others.
BET Inhibitors Pipeline Analysis